You’ve found a treatment that might help your treatment-resistant depression (TRD), but you’re not sure if insurance will cover it—or if you can afford it if they won’t. You’re worried about starting something you can’t financially sustain, but you also can’t keep living like this.
Insurance coverage for treatment-resistant depression therapies varies significantly based on the specific treatment, your insurance type, and whether you meet medical necessity criteria. FDA-approved SPRAVATO® (esketamine) is covered by most major insurance plans when you’ve failed at least two adequate antidepressant trials, while off-label IV ketamine therapy typically requires out-of-pocket payment (Kadakia et al., 2021). Understanding how coverage works, what documentation you need, and what your actual costs might be helps you make informed decisions about which treatments are financially feasible.
Understanding Medical Necessity and Prior Authorization
Insurance companies base coverage decisions on “medical necessity”—whether a treatment is appropriate and necessary for your specific medical condition according to established criteria. For treatment-resistant depression therapies, medical necessity typically requires documented evidence that standard first-line treatments haven’t provided adequate relief.
For SPRAVATO®, the FDA-approved esketamine nasal spray, medical necessity criteria typically include: diagnosis of major depressive disorder with treatment-resistant features (ICD-10 code F33.2), documented failure of at least two antidepressant trials from different pharmacological classes, evidence that each trial was adequate (proper dose and duration), current symptom severity requiring intervention, and absence of contraindications to esketamine treatment (Kadakia et al., 2021).
Prior authorization is the process through which your healthcare provider submits documentation to your insurance company proving you meet these criteria. This documentation includes your diagnosis codes, complete treatment history with medications, doses, durations, and outcomes, current depression severity scores from standardized assessments, and clinical justification for why SPRAVATO® is appropriate for your situation rather than trying additional standard medications.
The prior authorization process typically takes 7-14 days, though some insurance companies respond faster or slower. During this time, your provider’s office submits required documentation and responds to any requests for additional information. If approved, your insurance covers the treatment according to your plan’s benefits—typically requiring copays or coinsurance but covering the bulk of costs. If denied, you can appeal the decision with additional documentation or pursue treatment with out-of-pocket payment.
At Allevate Health in Princeton, our team assists with prior authorization for SPRAVATO®, submitting required documentation and working with insurance companies to obtain coverage for qualifying patients. This administrative support removes a significant barrier that often prevents patients from accessing treatments they need.
What Insurance Typically Covers—and What It Doesn’t
Understanding which treatments have insurance coverage and which require out-of-pocket payment helps you evaluate realistic options given your financial situation.
SPRAVATO® (esketamine nasal spray): This FDA-approved treatment for treatment-resistant depression is covered by Medicare and most major commercial insurance plans including Aetna, Cigna, Blue Cross Blue Shield, United Healthcare, and others (Kadakia et al., 2021). Coverage requires meeting medical necessity criteria—typically two failed antidepressant trials—but once approved, the treatment is covered like other prescription medications. Your out-of-pocket costs depend on your specific plan: some patients pay only copays ($30-100 per session), while high-deductible plans may require you to meet your deductible first. SPRAVATO® requires administration at certified treatment centers with two hours of monitoring, which may have separate facility fees—check with your insurance about coverage for both the medication and administration.
IV ketamine therapy: When used for depression, anxiety, or PTSD, IV ketamine is considered off-label use—meaning the medication (ketamine) is FDA-approved, but not specifically for this indication. Most insurance plans do not cover off-label IV ketamine for psychiatric conditions. This means patients typically pay out-of-pocket for IV ketamine therapy. At Allevate Health, IV ketamine infusions cost $600 per session, with a recommended initial series of 6 infusions ($3,600 total). Payment plans through Advanced Care are available to make this more manageable, but insurance coverage should not be expected.
Ketamine-assisted psychotherapy (KAP): This integrated approach combining ketamine administration with psychotherapy sessions is generally not covered by insurance, as it involves both the off-label ketamine component and therapy sessions that may not meet insurance criteria for standard psychotherapy billing. KAP costs vary based on provider and session frequency but typically require out-of-pocket payment.
Traditional augmentation strategies: Medications added to your antidepressant (like aripiprazole, quetiapine, or lithium) are typically covered by insurance when prescribed for treatment-resistant depression. These augmentation strategies may be worth exploring before or alongside ketamine-based approaches, particularly if insurance coverage is a significant factor in your decision-making.
Documentation You’ll Need for Insurance Coverage
If you’re pursuing insurance coverage for SPRAVATO®, having thorough documentation of your treatment history significantly speeds the prior authorization process and increases approval likelihood.
Essential documentation includes detailed records of previous antidepressant trials showing: specific medication names and classes, starting dates and ending dates, maximum doses achieved, duration at therapeutic dose, clinical response or lack thereof, and reasons for discontinuation (inadequate response, intolerable side effects, etc.). This documentation must show that you completed at least two adequate trials—therapeutic doses for sufficient duration—from different pharmacological classes.
Your current depression severity also needs documentation through standardized assessment scales like the HAM-D or MADRS. These objective measures demonstrate that despite previous treatment attempts, you’re still experiencing significant depression symptoms requiring alternative interventions. Your provider will complete these assessments during your evaluation.
Medical records from previous prescribers can support your case, though they’re not always necessary if you can provide detailed treatment history. If you switched providers frequently or received treatment from multiple clinics, gathering these records may take time—but the investment can make the difference between approval and denial.
Insurance companies may also request documentation ruling out factors that could limit treatment response: thyroid function test results showing no untreated hypothyroidism, substance use screening showing no active untreated substance use disorders, and confirmation that you’re continuing psychotherapy or other appropriate concurrent treatments. Having this documentation ready prevents delays in the authorization process.
At Allevate Health, our board-certified physicians with 18 years of medical practice experience complete comprehensive evaluations that generate the documentation needed for prior authorization. We assess not just whether you meet treatment-resistant depression criteria, but also document the clinical rationale for why SPRAVATO® or other ketamine-based approaches are medically appropriate for your specific presentation.
Out-of-Pocket Costs When Insurance Doesn’t Cover TRD Treatment
When insurance doesn’t cover your treatment, understanding actual costs helps you determine whether treatment is financially feasible and plan accordingly.
For IV ketamine therapy at Allevate Health, the cost structure is straightforward: $600 per infusion session. The initial treatment series typically involves 6 infusions administered over 2-4 weeks (usually twice weekly), totaling $3,600. After the initial series, maintenance infusions are scheduled based on individual response—some patients need sessions every 2-4 weeks, others remain stable for months between treatments. Maintenance costs therefore vary by individual needs, ranging from $600 monthly to $1,200-1,800 quarterly depending on your response pattern.
Payment plans through Advanced Care allow you to finance treatment costs over time rather than paying the full amount upfront. These plans can make treatment accessible when lump-sum payment isn’t feasible, though you should understand the terms including interest rates and repayment schedules before committing.
Some patients use Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to pay for ketamine therapy, which provides tax advantages even when insurance doesn’t cover treatment. Check your HSA/FSA plan rules regarding coverage for psychiatric treatments—most allow these expenses, but confirming beforehand prevents surprises.
The financial investment in ketamine therapy must be weighed against the costs of ongoing treatment-resistant depression: lost productivity at work, inability to advance in your career, relationship strain, other healthcare costs from depression-related medical issues, and quality of life impairment. This doesn’t diminish the reality that $3,600 is significant money—it means considering the full picture when evaluating whether treatment is worth pursuing financially.
For patients concerned about sustaining maintenance costs long-term, discuss this openly during your consultation. Some patients respond so well to the initial series that they need only occasional maintenance over years. Others require more frequent ongoing treatment. Understanding likely maintenance needs for someone with your clinical presentation helps you plan whether treatment is sustainable financially beyond just the initial series.
How to Navigate Insurance Denials and Appeals
If your prior authorization for SPRAVATO® is denied, the process doesn’t necessarily end there. Insurance denials can often be successfully appealed with additional documentation or clarification.
Common reasons for initial denial include: insufficient documentation of previous treatment trials (insurance needs specific doses and durations, not just medication names), inadequate trial duration (insurance may claim you didn’t stay on medications long enough to assess effectiveness), lack of documentation that trials were from different pharmacological classes, or missing information about current symptom severity. Many initial denials result from incomplete submissions rather than genuine ineligibility (Pilon et al., 2019).
Your provider can submit an appeal with additional documentation addressing the denial reason. This might include: more detailed treatment history showing adequate doses and durations, clinical notes from previous providers documenting treatment failures, current assessment scores showing continued symptom severity, and peer-reviewed literature supporting SPRAVATO® use for your specific presentation.
Some insurance companies require “step therapy” or “fail first” policies—meaning you must try and fail specific treatments (often generic medications or older treatments) before they’ll approve newer or more expensive options like SPRAVATO®. If you’ve already tried and failed the medications required by step therapy, your appeal should document this clearly. If you haven’t tried required medications, you may need to complete those trials before SPRAVATO® coverage is approved—frustrating, but understanding this upfront prevents surprise denials.
If appeals through insurance don’t succeed, some patients pursue treatment with out-of-pocket payment for IV ketamine therapy instead. While SPRAVATO® and IV ketamine work through similar mechanisms, the practical differences matter: SPRAVATO® is insurance-covered when approved but requires specific protocols and twice-weekly clinic visits initially. IV ketamine requires out-of-pocket payment but offers more dosing flexibility and the treatment series can sometimes be completed faster. Neither approach is inherently better—they’re different options with different practical and financial implications.
Medicare and Medicaid Coverage Patterns
Coverage for treatment-resistant depression therapies varies between Medicare, Medicaid, and commercial insurance, with important distinctions that affect your access to treatment.
Medicare increasingly covers evidence-based treatments for treatment-resistant depression including SPRAVATO® when medical necessity criteria are met. Medicare Part B typically covers the medication and administration when provided in certified treatment settings, though you’ll pay your standard Part B coinsurance (typically 20% after meeting deductible). Medicare Advantage plans may have different coverage structures—check with your specific plan. Medicare generally does not cover off-label IV ketamine for psychiatric indications.
Medicaid coverage varies significantly by state, as states set their own policies within federal guidelines. Some state Medicaid programs cover SPRAVATO® for treatment-resistant depression with prior authorization, while others have more restrictive policies or exclude newer treatments. New Jersey Medicaid has covered SPRAVATO® for eligible patients, but specific policies can change—verify current coverage with your Medicaid plan before assuming approval (Rossom et al., 2016).
Commercial insurance policies vary widely by carrier and specific plan. Large national carriers like Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare generally cover SPRAVATO® with prior authorization, but specific requirements differ. Some plans have more stringent criteria (requiring three or four failed medication trials rather than two) or restrict which providers can administer treatment. Review your specific plan’s coverage policy for treatment-resistant depression or esketamine specifically—general “mental health coverage” information may not include details about specialized treatments.
If you have insurance through your employer, your HR department or benefits administrator can often provide clarity about coverage for specific treatments. Many people never explore this resource, assuming insurance websites have complete information—but benefits staff can sometimes advocate for coverage or clarify policies in ways that help you access treatment.
Making Treatment Decisions Based on Financial Reality
The unfortunate reality is that financial considerations significantly influence mental health treatment decisions. Understanding your options within financial constraints helps you make practical choices rather than pursuing treatments you can’t sustain.
If insurance covers SPRAVATO® and you meet criteria: This is typically the most financially accessible path to ketamine-based treatment for treatment-resistant depression. While copays and coinsurance still create costs, they’re generally more manageable than full out-of-pocket payment. Pursuing prior authorization makes sense as a first step, even though the process takes time.
If insurance won’t cover SPRAVATO® but you can afford IV ketamine therapy: Out-of-pocket IV ketamine remains an option, particularly if you can use HSA/FSA funds or qualify for payment plans. Consider whether you can sustain not just the initial series ($3,600) but realistic maintenance costs based on typical response patterns for people with presentations similar to yours.
If ketamine-based treatments aren’t financially feasible right now: This doesn’t mean you’re out of options. Generic augmentation strategies (lithium, aripiprazole) are typically covered by insurance. Intensive psychotherapy approaches, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) may be covered depending on your plan. While these alternatives work through different mechanisms than ketamine, they remain viable options for treatment-resistant depression when cost is prohibitive.
At Allevate Health in Princeton, New Jersey, we discuss costs and insurance coverage transparently during complimentary consultations. Understanding your financial reality is part of comprehensive treatment planning—we’d rather help you identify feasible treatment options than recommend approaches you can’t afford to complete. Our goal is finding effective treatment that fits your clinical needs and practical circumstances.
Practical Steps to Determine Your Coverage This Week
- Call your insurance company’s member services line. Ask specifically about coverage for esketamine (SPRAVATO®) for treatment-resistant depression. Get the name of the representative and document what they tell you. Ask: “Does my plan cover esketamine/SPRAVATO® for treatment-resistant depression? What criteria must I meet? Is prior authorization required? What would my out-of-pocket costs be (copay, coinsurance, deductible)?” Document responses in writing—verbal information from insurance companies is sometimes incorrect, so having names and dates helps if you need to follow up.
- Review your treatment history documentation. List every antidepressant you’ve tried with specific details: medication name, maximum dose, duration at that dose, and outcome. Identify whether you’ve completed at least two adequate trials from different classes—if so, you likely meet basic medical necessity criteria for SPRAVATO®. If your trials were inadequate (too low dose, too short duration), understanding this now helps you plan whether pursuing insurance coverage makes sense or whether completing adequate standard trials should come first.
- Schedule a consultation to discuss coverage options. At Allevate Health, complimentary consultations include discussion of insurance coverage, prior authorization process, and out-of-pocket costs for patients who don’t have coverage. Call 640-252-9785 to schedule. During this consultation, you’ll receive specific guidance about whether you’re likely to obtain insurance approval for SPRAVATO® or whether IV ketamine therapy with out-of-pocket payment might be more practical given your situation.
Understanding the Value Equation Beyond Just Cost
While cost is a legitimate consideration, the value equation includes factors beyond dollar amounts. Treatment-resistant depression significantly impairs functioning across multiple life domains—work productivity, relationship quality, physical health, and overall life satisfaction.
Research on the economic burden of treatment-resistant depression shows that patients incur substantially higher healthcare costs over time due to increased emergency room visits, hospitalizations, medical complications, and lost work productivity (Kadakia et al., 2021). Finding effective treatment that improves functioning can actually reduce overall costs when considering these broader economic impacts.
This doesn’t mean you should pursue treatment you genuinely can’t afford—financial stress itself worsens depression. It means considering the full picture: What is treatment-resistant depression costing you in lost opportunities, damaged relationships, career stagnation, or decreased quality of life? How does that compare to the financial cost of pursuing specialized treatment?
Some patients conclude that the financial investment is worthwhile even when insurance doesn’t cover treatment. Others determine that pursuing less expensive alternatives makes more sense given their financial reality. Both decisions are valid—what matters is making informed choices based on complete understanding of costs, coverage options, and your specific circumstances.
To learn more about insurance coverage for treatment-resistant depression therapies or to discuss your specific coverage situation, contact Allevate Health in Princeton, New Jersey at 640-252-9785 or visit allevatehealth.com. Our team can help you navigate insurance prior authorization for SPRAVATO®, discuss out-of-pocket options for IV ketamine therapy, and identify treatment approaches that align with both your clinical needs and financial circumstances.
References
Kadakia, A., Dembek, C., Heller, V., Singh, R., Ayer, D., Mate, R.A., Ravindranath, D., Hough, D., & Daly, E.J. (2021). Economic burden of treatment-resistant depression among commercially insured US patients. American Journal of Managed Care, 27(4), 140-147. https://www.ajmc.com/view/economic-burden-of-treatment-resistant-depression-among-commercially-insured-us-patients
Pilon, D., Sheehan, J.J., Szukis, H., Singer, D., Jacques, P., Lejeune, D., & Lefebvre, P. (2019). Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clinical Therapeutics, 41(6), 1199-1216. https://www.clinicaltherapeutics.com/article/S0149-2918(19)30150-7/fulltext
Rossom, R.C., Solberg, L.I., Vazquez-Benitez, G., Crain, A.L., Beck, A., Whitebird, R., & Glasgow, R.E. (2016). Insurance coverage and detection of depression treatment among people with mental disorders. Journal of Mental Health Policy and Economics, 19(3), 123-132.